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Abstract: 
Protein aggregation can be highly detrimental to organisms, and has been 
associated with diseases including Alzheimer’s, Huntington’s, type II diabetes, and 
transmissible spongiform encephalopathies such as Mad Cow disease.  There is no single 
amino acid sequence responsible for aggregation into amyloid-like structures, but rather a 
large range of amyloidogenic peptides have been discovered.  A fragment of the yeast 
Sup35 prion, GNNQQNY, has been found to aggregate using a “dry, steric zipper” 
structure.  This study looks at mutants of GNNQQNY in order to elucidate the exact 
contributions of various amino acids to the aggregation process.  The data shows that 
Gly1 is important to the overall aggregation of the peptide, and that a deletion of the 
amino acid reduces the formation of larger amyloid structures.  Mutating Asn2 or Asn6 to 
Leu2 or Leu6 was shown to reduce the rate of aggregation.  A mutation of Asn3 to Leu3, 
however, seemed to drastically accelerate aggregation.  This research lays an important 
groundwork for future studies into the driving forces of peptide aggregation. 
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Introduction: 
 
Protein Aggregation 
 
Peptides are among the most fundamental building blocks of life; their structural 
and enzymatic functions are what make even the simplest organisms possible.  The amino 
acid sequence, known as the primary structure, and the initial folding of the chain into 
helices or pleated sheets, known as the secondary structure, are both vital to the function 
of the polypeptide.  The tertiary and quaternary structures, or the way that peptides fold 
and assemble into larger proteins, are even more important to protein function.  This is 
because the three-dimensional shape is a major determinant of how the protein works.  
Misfolding can lead to a broken or ineffective version of the molecule that is unable to 
perform its normal tasks, causing disease or death of the organism.  Similarly, the 
aggregation and deposition of polypeptides can be highly dangerous, and has been linked 
to diseases including Alzheimer’s, Huntington’s, type II diabetes, and transmissible 
spongiform encephalopathies such as Mad Cow disease. 
There are many different forms of protein aggregation.  Technically, any protein 
can be made to aggregate through certain processes.  For example, increasing the salt 
concentration can force the native folded proteins to amass together and precipitate out of 
solution.  Such precipitates are easily dissolved, however, and cannot be truly classified 
as protein aggregates (1).  True protein aggregation involves the cohesion of partially 
folded polypeptides into a large insoluble mass.  Depending on the proteins involved, this 
mass can either be random and disordered or highly organized (1).   
One common protein aggregate is known as an “inclusion body”.  Inclusion 
bodies are disordered aggregated structures that are generally produced by the over-
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expression of proteins in cells.  Although they are most commonly observed when a 
foreign protein is expressed in a bacterium, inclusion bodies can be found in many 
different cell types, from prokaryotes to eukaryotes (2).  The general mechanism of 
aggregation is believed to involve intermolecular interactions between partially folded 
proteins.  Essentially, as the peptide chain folds, it reaches a point where its aggregation 
potential is the highest.  If there is a high concentration of similarly folded peptides, an 
interaction is more likely.  Once the proteins begin to assemble together, they create an 
insoluble aggregate (1).  This aggregate is considered to be disordered because it lacks 
the highly ordered superstructure of amyloid fibers.  However, there is still a significant 
structural factor in the assembly of inclusion bodies; like amyloids, they have been found 
to form stacks of β-sheets.  Furthermore, it has been shown that inclusion bodies can act 
as nucleation seeds. Once a small aggregate has formed, it will provide a location for 
other partially folded proteins to latch on and increase the size of the body.  In essence, 
the presence of an inclusion body can induce further aggregation (2). 
There are both beneficial and detrimental aspects of inclusion body formation.  
Such aggregates can be useful in the purification of peptides from transformed bacteria.  
Since the over-expressed proteins have gathered together into an insoluble mass, they can 
easily be separated from the rest of the cell.  Furthermore, due to the overproduction of 
the single polypeptide and the ability of the inclusion body to induce further aggregation, 
the proteins found in the aggregates are generally homogenous and pure (1).  Despite this 
potential benefit, there are still many negative effects of inclusion body formation.  
Because the proteins are in partially folded states, it can be difficult to return them to 
their native forms.  Since misfolded proteins often lose their function, the researcher’s 
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ability isolate functional proteins from the cells may be limited.  Furthermore, if the 
peptides aggregate in an irreversible manner they cannot be properly studied (1, 2). 
 
Amyloids 
Perhaps the most studied protein aggregates in recent years have been amyloid 
plaques.  Amyloids are highly ordered proteinaceous masses that form into fibrils 
approximately 80 to 100 angstroms in width.  They were first discovered by Rudolph 
Virchow in 1854.  Believing the fibers to be carbohydrate based, he dubbed them 
“amyloids”.  It was later discovered that the amyloids were actually made of proteins (3).  
Since that time, extracellular amyloid plaques have been found to be associated with 
many human disorders, most notably Alzheimer’s disease. 
For a protein aggregate to be considered an amyloid, it must fulfill three 
requirements: the formation of fibers visible in electron microscopy; the ability to bind to 
the dye Congo Red; and high β-sheet content in the structure (1).  While the formation of 
fibers represents the important superstructure associated with disease plaques, the β-sheet 
content of the secondary structure is also significant.  In an amyloid, much of the normal 
secondary structure converts to β-sheets.  These β-sheets stack together along the width 
of the fibril, forming what is known as the “cross-β structure” (3).  The sheets themselves 
run parallel to the fibril axis, while the β-strands are perpendicular to it.  Furthermore, 
some evidence now shows that the β-sheets form a helix, twisting around a common axis 
(4).  These characteristics are common to all amyloids, regardless of the precursor 
proteins from which they were formed. 
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As the amyloid grows, its kinetics appear to be sigmoidal; there is a lag phase, 
followed by a rapid growth, eventually reaching a plateau.  This is consistent with 
nucleation processes (5, 6).  As with inclusion bodies, the amyloid aggregate forms more 
quickly when it has a preformed oligomer to attach to.  To make the initial dimer, the 
peptides first begin to form β-sheets with each other.  Once they are held together, the β-
strands are open for further interactions.  More peptides can now join the growing β-
sheet, forming an oligomeric structure.  These oligomers then interact with each other, 
creating the fibrils characteristic of amyloids (6).  The initial β-sheet may be slow to form 
but, once it has, it becomes easier for other peptides to bind, thereby increasing the 
elongation rate.  Furthermore, studies have shown that some amyloidogenic peptides 
have an “anti-chaperone” activity.  A segment of the Alzheimer’s β-peptide, known as 
Aβ(25-35) has been observed to actually break the native conformation of the unrelated 
protein firefly luciferase.  Through its electrostatic interactions, the peptide was able to 
induce aggregation and even damage the proteins that remained in solution (7).  This 
anti-chaperone characteristic may be important to amyloid formation.  It is possible that 
some amyloids may be able to alter the native states in vivo, allowing for further 
aggregation. 
Such amyloid formation becomes a problem because the aggregates formed are 
insoluble and unlikely to break apart.  This is to the relative stability of the β-sheet 
structure compared to other secondary structures (8).  While it is thermodynamically 
favorable for random coils or helices to coalesce together, these interactions are not as 
favorable as the formation of β-sheets.  Therefore, once two proteins have aggregated 
into a β-sheet dimer, it requires energy to separate them into any other form.  Since there 
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is no natural reason to break apart, the peptides remain aggregated, and eventually build 
up into an amyloid fibril.  In fact, this thermodynamic preference can be even stronger 
than the favorability of the native globular state of the protein (8).  This is why cells often 
use chaperones to ensure the proper folding of the peptide chains; without these 
molecules to guide the structural formation, aggregation would be a more common event 
(1, 9). 
A major classification of amyloidogenic proteins is the “proteinaceous infectious 
particles”.  Better known as prions, these are proteins whose natural conformation has 
been altered, often allowing them to aggregate into amyloid-like fibers.  The aggregates 
are insoluble, and are resistant to proteases (1).  Several diseases known as “transmissible 
spongiform encephalopathies”, including Mad Cow disease and Creutzfeldt-Jacob 
disease, have been attributed to prions (1, 10).  What makes prions notable from other 
aggregating peptides is that they are known to catalyze the alteration of other molecules’ 
native conformations.  Essentially, if a protein becomes a prion, it has the ability to alter 
the shapes of similar proteins, turning them into prions.  This function is usually very 
specific for self-aggregation; a prion of a certain protein will only affect molecules of that 
protein (11).  Because of this, prions are known as an epigenetic factor, meaning they can 
be inherited without altering the genome (9).  This is also why such spongiform 
encephalopathies are transmissible.  If a healthy organism is infected with the prion 
protein, its own proteins may be altered, causing aggregation and the formation of the 
typical plaques. 
Interestingly, prions may not always be detrimental.  Because evolution seems to 
have conserved prion-forming domains, it would seem that they have some benefit (11).  
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It is possible that cells use this function to deal with over-expression or environmental 
stresses.  Also, the fact that each prion will only affect very specific proteins keeps the 
function in check, and allows for several of such systems to be in place in a single cell. 
 
Cytotoxicity 
There are several reasons why amyloids are dangerous in cells.  Clearly the 
insoluble deposits can have a reducing effect on the total concentration of protein in 
solution.  This could potentially strip the cell of vital enzymes or structural peptides.  
More important, however, seems to be the effects that amyloids have on cell membranes.  
These surfaces form an interface along which β-sheets can assemble, creating amyloid 
fibers near the edge of the cell (12).  Interestingly, it is not the mature fibrils, but rather 
the oligomeric structures that are believed to be cytotoxic to the cells (6, 13).  The 
mechanism for such cytotoxicity involves the formation of pores in the cell membranes, 
making the membrane permeable to some ionic molecules.  This is especially important 
in neurological diseases such as Alzheimer’s, where uncontrolled pores could destroy the 
ion potentials needed for nerve cell function (13, 14). 
The formation of such non-native transmembrane channels can be observed in 
bacterial pore-forming toxins, which are proteins used to disrupt the ion balance of target 
cells.  These pores are created using a series of β-strands in a ring known as a β-barrel 
(15).  Unlike normal cellular β-barrel channels, they are assembled from several separate 
peptide chains instead of a single continuous peptide (14).  Such structures can penetrate 
the cell membrane, connecting the cytoplasm and the extracellular environment and 
allowing ions to flow freely in and out of the cell (15). 
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Similarly, β-sheet aggregates have been shown to puncture cell membranes.  Like 
in pore-forming toxins, it has been demonstrated that separate peptides can aggregate 
together to successfully create a channel out of β-strands (14).  Moreover, these β-barrel 
structures may assemble together to form even larger pores.  This ability has been 
observed particularly in peptides with repeats of hydrophobic amino acids, glycine, and 
serine.  It was also determined that the dye Congo Red could inhibit this formation.  This 
is strong evidence that the pore is being created by peptides aggregated into oligomers, 
since the dye is known to bind to amyloids (14).  Similar experiments have shown that 
aggregate-formed pores are capable of allowing calcium ions and reactive oxygen species 
into the cytoplasm, which could be highly detrimental to a living cell (13). 
In order to form a dangerous pore in the cell membrane, the peptides must first 
penetrate the membrane.  This process is believed to be related to the natural assembly of 
the β-sheet structures along the edge of the cell due to van der Waals interactions 
between the peptides and the membrane lipids (12, 16).  Peptides in a random coil 
formation begin to form very disordered aggregates in solution.  Upon contacting the 
phospholipids of the cell membrane, the aggregate reassembles into β-sheets.  With 
hydrophobic regions now exposed along the sheet, it naturally begins to insert itself into 
the membrane in order to access the hydrophobic tails of the phospholipids.  Once inside 
the membrane, the β-sheets continue to interact, assembling the β-barrel structures and 
creating the membrane channels (14).  A similar process has been shown to occur with 
the Alzheimer’s amyloid β-peptide, known as Aβ.  Once cleaved from the Alzheimer’s 
precursor protein, Aβ finds and associates with “lipid rafts”, or clusters of specific 
membrane lipids.  Upon interaction with the lipid raft, Aβ changes its conformation from 
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α-helix to β-sheet, and forms the starting point for aggregation (17).  From there, the 
peptide can penetrate the cell membrane, disrupting vital neural ion potentials. 
Fortunately, in at least some cases the cells can be saved even after the oligomeric 
species have formed ion channels, as long as the damage has not been too severe (13).  
This allows for the possibility of treatment for amyloidogenic diseases.  Since more and 
more diseases are being attributed to protein deposition, including Alzheimer’s, 
Huntington’s, spongiform encephalopathies, Parkinson’s, and Type II diabetes, 
treatments for peptide aggregation are being heavily researched (15, 18). 
 
Modulating Factors for Aggregation 
The effects of many small molecules, ranging from ions to other peptides, on the 
aggregation of Alzheimer’s Aβ have been studied.  Some, particularly glycerol and metal 
cations, were found to actually accelerate the aggregation process (19).  On the other 
hand, monoclonal antibodies that target the Aβ peptide have had interesting effects on 
Alzheimer’s disease.  While they have not been shown to affect the amyloid plaque, there 
is evidence that antibodies can reduce the memory impairment associated with the 
disease (20).  This is possibly due to the binding of the antibody to the soluble peptides.  
Since it is believed to be the oligomeric species that cause cytotoxicity, and not the 
mature fibrils, the antibodies may inhibit the effects of the oligomers without actually 
stopping the formation of the aggregated plaques. 
Interestingly, modified peptides have proven to be a rather effective means of 
inhibiting aggregation.  By introducing small peptides that aggregate preferentially with 
the target protein, amyloid formation can be prevented.  Fragments of Aβ that can inhibit 
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the native aggregation have been identified, and have been modified to increase their 
usefulness.  In particular, a cholyl-LVFFA-OH made with D-amino acids, instead of the 
natural L-amino acids used is organisms, is capable of effectively blocking the amyloid 
formation while remaining stable in a biological environment (21).  This an important 
factor in designing an inhibitory peptide: not only must it be effective in reducing 
aggregation, but it also must be stable in cells so that it has time to function. 
Another effective Aβ inhibitor has been designed to block the KLVFF region of 
the native peptide; it was created using alternating natural amino acids and α,α-
disubstituted amino acids (22).  These modified amino acids have the side-chains and the 
hydrogen replaced with various larger groups.  Like the native peptide, the ααAA peptide 
is able to form β-sheets with other Aβ molecules.  The extra side groups, however, block 
the β-sheet formation on one edge.  Since other peptides cannot interact with this 
modified edge, the ααAA peptide effectively caps the sheet, and the aggregate loses its 
ability to grow.  This design also ensures that the modified peptides will not self-
aggregate, since they cannot interact with each other (22).  Overall, such modified 
peptides have been shown to be effective ways to specifically target Aβ and to inhibit the 
formation of amyloids. 
Since protein deposition may be detrimental to cells, it is not surprising that 
evolution has selected against peptides with high aggregation potentials (23).  Generally, 
hydrophobic residues are kept within the protein’s core.  Since the hydrophobic regions 
will tend to come together to avoid the aqueous environment, this encourages proper 
folding, while keeping such regions away from other proteins.  Similarly, β-sheets are 
usually protected internally, because external β-strands have the potential to interact and 
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form aggregates.  Moreover, the β-sheets are often twisted into a β-barrel structure.  
Having no open ends, the sheets cannot connect to other peptides.  In the cases where 
there is an external β-sheet, there is usually a loop or helix to protect it from extraneous 
interactions.  In many polypeptides, the primary structure of the peptide has been 
designed to avoid β-strands.  Such segments will contain glycines or prolines, which 
discourage β-sheet formation.  Peptides rarely have alternating polar and non-polar 
residues, which tend to form amyloidogenic regions (23).  Similarly, adjacent regions of 
proteins tend to have a varied amino acid composition, which makes aggregation less 
likely.  Interestingly, some mutations in wild-type peptides have been predicted to further 
reduce aggregation potential, indicating that evolution has not completely protected the 
proteins (24).  Perhaps fully protecting the peptides from aggregation would interrupt 
certain vital functions, such as the ability to interact with other peptides via glutamine 
and asparagine rich regions (11, 25).  Alternatively, it is possible that the proteins have 
simply been protected enough to prevent aggregation within a reasonable life span (24). 
 
Aggregating Sequences 
One of the major reasons that proteins needed to evolve specific defenses against 
amyloidogenic species is that aggregation seems to be a generic property of peptide 
chains.  There is no specific sequence of amino acids that causes protein deposition.  
Rather, many different and unrelated sequences are capable of forming aggregates (23).  
Originally this quality was believed to be solely found in hydrophobic regions, but it has 
now been observed in a variety of hydrophilic amino acid sequences as well.  Even the 
size of the amyloidogenic peptides is inconsistent; for example the commonly studied 
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forty-two amino acid Aβ42, compared to the fibril forming tetrapeptide DFNK (18).  
However, the most important factor for aggregation propensity seems to be the ability of 
the peptide to form β-sheets.  Certain amino acids favor the β-strand structure more than 
others, based on the steric interactions between the amino acid side chain and the 
backbone (26).  However, a higher likeliness to form a β-sheet does not necessarily 
indicate a higher rate of aggregation.  Instead, peptides that can aggregate slowly but 
steadily build more fibrils.  It is important for the peptide to be able to convert to β-
sheets, but these must polymerize at a rate that will allow the super-structure to form 
(25).  Just as mutations affecting the ability to form β-sheets have a significant effect on 
the ability of the peptide to aggregate, so do those that affect hydrophobicity and charge.  
These three factors can be used to estimate the aggregation propensity of a given 
polypeptide chain (24). 
Among the various amyloidogenic peptide sequences, hydrophobic regions 
remain amongst the most important and best studied.  This is because the amyloidogenic 
properties of Alzheimer’s Aβ peptide are based on its highly hydrophobic nature.  There 
are several hydrophobic segments in Aβ.  Among these, the central region has often been 
considered to be the most important, but others including the C-terminal region have also 
been shown to be significant.  Mutating residues in these regions to hydrophilic amino 
acids causes a reduction in aggregation rates, although certain mutations have greater 
effects than others (27).  Such mutations will also affect the thermodynamics of the 
aggregation, reducing the overall amount of amyloid formed (28).  In fact, the 
hydrophobicity of Aβ is so important that randomly mutating the hydrophobic regions of 
the peptide with different hydrophobic amino acids does not disrupt the ability to 
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aggregate.  While this will cause some minor differences in kinetics and fibril structure, 
any of the hydrophobic residues can be replaced with any other, and the peptide will still 
maintain its amyloidogenic properties.  Essentially, it is the hydrophobicity, and not the 
specific amino acid sequence, which gives Aβ its ability to form aggregates (29).  
Therefore, if the hydrophobicity is increased by a mutation, then the aggregation rate and 
the thermodynamic favorability of the reaction will also increase (28).  There are still 
other important factors, however, such as β-sheet propensity and overall peptide charge.  
Altering these features affects the amyloid formation, and is responsible for the 
differences in kinetics and fibril morphology seen when random hydrophobic mutations 
are made (30).  Overall, the hydrophobicity of the amino acid sequence is what causes Aβ 
to aggregate, although β-sheet propensity attenuates the rate. 
Many hydrophobic peptides other than Aβ have demonstrated tendencies to 
aggregate.  The hexapeptide NFGAIL, from the human islet amyloid polypeptide (IAPP), 
is highly hydrophobic, and has been shown to form amyloid fibrils (31).  Hydrophobic 
forces will cause this peptide to form a disordered association with an oligomeric 
aggregate.  Such an interaction is highly favorable because it reduces the amount of water 
molecules around the hydrophobic residues.  After the random coil NFGAIL has 
associated with the ordered oligomer, it will shift its structure to form a β-sheet with the 
rest of the aggregate, further reducing the overall energy state (31). 
Other hydrophobic aspects of peptide chains can aid in aggregation, even in 
predominantly hydrophilic peptides.  Regions of alternating hydrophobic and hydrophilic 
residues favor β-sheet formation, and therefore are often indicative of amyloidogenic 
peptides (29).  Similarly, aromatic residues are important for amyloid formation.  
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Aromatic ring structures have been shown to stack together in aggregates of the 
hydrophilic peptides DFNKF and GNNQQNY.  This provides a stabilizing force for the 
aggregate, allowing the amyloid to grow (10, 18, 32). 
While generic hydrophobic regions are sufficient to cause aggregation, there are 
some specific amino acid sequences that have been implicated as well.  Using mutants of 
the peptide STVIIE, certain basic patterns of amyloidogenic amino acid sequences have 
been found.  These patterns have been shown to correspond to actual aggregating 
peptides.  While it is unlikely that the patterns can be used to describe all aggregating 
peptide regions, it is an important step in identifying polypeptides with the potential to 
form amyloids (25). 
An important type of hydrophilic region that has been found to cause peptides to 
aggregate involves high glutamine and asparagine content.  Regions rich in Q or N have 
been observed in several aggregating proteins, including the yeast prion Sup35 and the 
Huntington Protein.  In fact, Q/N-rich domains can be found in a large variety of proteins 
in organisms ranging from bacteria to eukaryotes.  Such domains appear in peptides far 
more commonly than can be explained by simple random chance, implying that these 
aggregation-prone regions are actually selected for by evolution.  The Q/N-rich regions 
probably perform an important cellular function, likely involving protein-protein 
interactions or self-aggregative properties.  Interestingly, thermophilic organisms tend to 
lack these domains, possibly due to the increased rate of aggregation at higher 
temperatures.  Prions form when a polypeptide containing such a region is not properly 
folded (11).  Normally, cells use chaperones to ensure that such domains remain 
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innocuous.  For example, chaperone molecules have a significant effect on whether the 
yeast prion Sup35 folds properly or becomes an amyloidogenic prion (9). 
 
Sup35 Fragment GNNQQNY 
A fragment from the Sup35 protein, the heptapeptide GNNQQNY (Figure 1A), 
has been identified as a region that can aggregate into amyloid fibrils.  Many computer 
simulations have been performed to study the aggregation process.  In solution, a single 
molecule of GNNQQNY is predicted to take a random coil structure.  Although the 
peptide is known to have a high aggregation propensity, the formation of an α-helix is 
actually more thermodynamically stable than a β-strand.  This energy barrier for β-strand 
formation slows aggregation, which explains why a nucleation seed helps speed the 
process (33).  When two GNNQQNY strands interact, they will transiently form a β-
sheet.  The sheet tends to take on an anti-parallel structure for the formation of the initial 
dimer, simply because the anti-parallel sheet requires less energy than the parallel sheet 
(10).  Because a β-sheet has now formed, however, the energy barrier for the next strand 
is lessened.  When the third peptide attaches, a parallel alignment is now favored (5).  
This effect is due to the C-terminal tyrosines; the aromatic rings stack upon one another, 
stabilizing the parallel structure (5, 32).  The formation of an anti-parallel sheet is 
allowed, but is less stable and therefore more likely to break apart.  Thus, the initial 
dimerization of GNNQQNY is based on an anti-parallel β-sheet, while further 
polymerization occurs via parallel alignments (5, 10). 
As the parallel β-sheet forms, they begin to take on the “dry, steric zipper” that is 
characteristic of aggregates formed by GNNQQNY and NNQQNY.  This structure is 
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unusual because it involves a dry interface free of water molecules, but is constructed by 
hydrophilic Q and N residues (34).  The steric zipper is possible due to the amino acid 
structure of the peptide.  According to computer models, there are many interpeptide and 
intrapeptide hydrogen bonds formed in addition to the backbone hydrogen bonds of the 
β-sheet.  Based on the general structure of the β-sheet, the side-chains at positions 1, 3, 5, 
and 7 point away from the dry interface, while positions 2, 4, and 6 point into it.  The 
Asn6 forms an intrastrand hydrogen bond with Gln4, while Asn3 hydrogen bonds with 
Gln5.  Meanwhile, the asparagines at positions 2, 3, and 6 form interstrand hydrogen 
bonds with their counterparts in the peptides above or below them.  These bonds 
effectively reduce the amount of water that can interact with the hydrophilic residues, 
which is entropically favored, since it releases water molecules from the interaction (33).  
Without the water, the β-sheet can behave as if it has a hydrophobic face, and will 
interact with another sheet to form a dry interface.  The steric interactions between the 
two sheets further favor this interaction, creating the “dry, steric interface”.  Essentially, 
the Asn2, Gln4, and Asn6 of two peptides associate together in opposite directions.  This 
interaction keeps the two β-sheets together, and aids in the aggregation of the peptides 
(34). 
 
Goals of this Study 
While many computer simulations of GNNQQNY or NNQQNY aggregation have 
been performed, few true chemical mutagenesis reactions have been reported.  Computer 
simulations are very useful, but it is still important to verify the models using real 
chemistry.  To that end, the peptides GNNQQNY and NNQQNY, the leucine mutants 
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GLNQQNY, GNLQQNY, GNNQQLY, LNQQNY, NLQQNY, and NNQQLY, and the 
valine mutants NVQQNY and NNQQVY were synthesized (Figures 1 and 2).  
Experiments were performed on these peptides to elucidate the importance of the specific 
amino acids and to determine the relative importance of steric factors and electrostatic 
interactions such as hydrogen bonding.  The aggregation of various peptides was studied, 
and an important groundwork was laid for future research into the driving forces of 
peptide aggregation. 
 
 
 17
Materials and Methods: 
 
Solid Phase Peptide Synthesis 
 Fmoc solid phase peptide synthesis was performed manually to make many of the 
peptides.  0.2mmol of Fmoc-Tyr-(tBu)-Wang Resin was used for each peptide.  The 
amino acids were added in a five-time excess, using 1mmol each.  The resin was first 
washed and swollen with dimethylformamide (DMF) for twenty minutes.  It was then 
deprotected using 20% Piperidine in DMF twice, each for ten minutes.  The amino acid 
to be added was activated using 0.9mmol 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), 1.4mmol of diisopropylethylamine 
(DIEA) and 2mL of DMF.  After two minutes, the reaction vessel was drained of DMF, 
and the activated amino acid was added and allowed to react for twenty minutes.  The 
reaction vessel was drained, and the resin was washed with DMF to remove excess 
reactants.  This process was repeated until all amino acids were added.  A final 
deprotection was performed to remove the Fmoc protecting group from the last amino 
acid, and the resin was allowed to dry. 
 Automated solid phase peptide synthesis was performed on the Protein 
Technologies Inc. Tribute Peptide Synthesizer, using similar procedures.  The reactions 
were run on either 0.1mmol of resin or 0.3mmol of resin scales, still using five 
equivalents of amino acid.  The amino acids were either prepackaged in vials with HBTU 
or were assembled in the lab.  DMF could be replaced with N-methyl-2-pyrrolidinone 
(NMP), and DIEA could be replaced with 0.40M N-methlymorpholine. 
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TFA Peptide Cleavage 
 Peptides were cleaved off the solid support resin using a trifluoroacetic acid 
(TFA) solution.  Generally for the peptide GNNQQNY and its leucine and valine 
mutants, water and triisopropyl silane (TIS) were sufficient scavengers to aid in the 
removal of protecting groups.  The solution was made to be 95% TFA, 2.5% water, and 
2.5% TIS, using about 1mL for every 100mg of resin and peptide.  For peptides with a 
larger array of protecting groups, Reagent K was used.  This solution contained 85% 
TFA, 4% water, 4% thianosole, 4% phenol, 2% 1,2-ethanedithiol (EDT), and 1% TIS.  In 
both cases the reaction was allowed to run for one hour before draining the TFA solution, 
now containing the peptide, into a beaker. 
 Normally, an ether precipitation would be performed.  This involves adding 
cooled diethyl ether into the solution to cause the peptide to crash out.  The solution 
would then be centrifuged, and the ether layer would be poured off.  This process would 
be repeated, and the solid would be allowed to dry. 
 Since GNNQQNY and its mutants have no charged residues, the peptides failed 
to crash out of solution in the presence of ether.  Instead, a cooled ten-to-one hexane-to-
ether mixture was added to the TFA solution and mixed.  The hexane layer, now 
containing many of the hydrophobic protecting groups, was then be poured off, while the 
TFA layer was evaporated down, and then diluted with HPLC buffer A. 
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HPLC Purification 
 The peptides were purified via High Pressure Liquid Chromatography (HPLC), 
using a Waters PrepLC System.  The HPLC used two buffers: buffer A was 95% water, 
5% acetonitrile, and 0.1% TFA, while buffer B was 95% acetonitrile, 5% water, and 
0.1% TFA.  Outflow was monitored using an ultraviolet and visible spectrophotometer, 
measuring absorbance at 220nm, for the peptide bond absorbance, and 280nm, for the 
tyrosine ring.  The peptides were run through a 250x30.00mm 10 micron column over a 
fifteen minute gradient of increased buffer B.  GNNQQNY and its mutants usually came 
off the column in sharp, distinct peaks when a 100%A, 0%B to 40%A, 60%B gradient 
was used.  The peaks were collected, and samples of the fractions were sent for mass 
spectrometry to verify the presence of the peptide.  The rest of the fractions were 
combined and evaporated down.  The peptide in water was then frozen and lypholized. 
 
LCMS 
 Liquid Chromatography/ Mass Spectrometry (LCMS) were performed using the 
Micromass LCT system.  This technique was used to assess the purity of the peptides 
after HPLC. 
 
NMR 
 Proton Nuclear Magnetic Resonance Spectrometry (NMR) was performed using 
the Varian Gemini 400MHz Nuclear Magnetic Resonance Spectrometer.  This was used 
to assess the identity and purity of peptides and thioflavin T. 
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Peptide Solution Preparation 
 The peptide solutions were prepared by dissolving solid peptide in dimethyl 
sulfoxide (DMSO), usually keeping the final DMSO content at 0.7%.  The solution was 
then diluted with buffer and then sonicated for twenty minutes.  To remove any 
aggregates, which could act as potential nucleation seeds, the solution was filtered 
through Millipore Ultracel YM-3 3kDa centrifuge filters.  The concentration was 
determined by measurement of absorbance at 280nm, and the solution was diluted to the 
desired concentration with buffer, keeping the DMSO content constant. 
 
Turbidity Measurement 
 Turbidity measurements were taken on the PerkinElmer Lambda25 UV/VIS 
spectrometer to monitor the aggregation kinetics of the peptides.  Absorbance of peptide 
solutions was monitored at 400nm for several days at 25°C, either with or without 
stirring. 
 
Monomer Assay 
 Post-aggregation monomer concentrations were measured.  The aggregate 
solution was centrifuged through 3kDa filters to remove the aggregated peptides.  The 
concentration of peptide remaining in solution was then measured via absorbance at 
280nm. 
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Fluorescence Spectrometry 
 Peptide aggregation was measured using Spex Fluorolog Fluorescence 
Spectrometer.  A peptide solution was prepared with 2mM thioflavin T.  The solution 
was excited at 440nm, and fluorescence was measured at 485nm. 
 
Recrystallization of Thioflavin T 
 Thioflavin T (ThT) was recrystallized to increase its purity.  The ThT was 
dissolved in the minimal amount of warm water.  The solution was cooled and filtered.  
The purified ThT crystals were collected and dried. 
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Results: 
 
Synthesized Peptides 
 
The peptides NNQQNY, LNQQNY, NLQQNY, NNQQLY, NVQQNY, 
NNQQVY, GNNQQNY, GNNQQLY, GLNQQNY, and GNLQQNY were synthesized 
using Fmoc solid phase peptide synthesis (Figures 1 and 2).  Each was then purified on 
the HPLC.  The purity of the peptides was assessed using proton NMR and LCMS.  
NMR data for GNNQQNY in D2O (Figure 3) indicates a high purity of the peptide, as 
there is no discernable impurity in the spectra.  Similarly, the LCMS data for the peptides 
demonstrate high purity.  A comparison the areas of the major peptide peaks to the 
impurities show GNNQQNY to be approximately 80% pure, and GLNQQNY to be 90% 
pure (Figure 4).  GNLQQNY, GNNQQLY, and NNQQNY and its mutants each have a 
purity of 95% or greater. 
 
Turbidity Measurements 
Kinetic studies of the peptide aggregations were performed by monitoring the 
absorbance of the solution at 400nm.  The first peptide studied was NNQQNY at 0.30 
mg/mL.  In a 10mM phosphate buffer at pH 7.4 and 25°C, very little change in 
absorbance was observed (Figure 5A).  The kinetic study did show a general rise in 
absorbance, which could potentially indicate aggregation, but the overall change was 
very small.  To test if the peptide was responsible for the slight increase, the buffer was 
run on the spectrometer alone (Figure 5A).  No increase in absorbance was observed, 
indicating that the peptide was the factor that caused the increase in absorbance. 
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Because the crystal structure of NNQQNY had been determined using high zinc 
cation concentrations (34), the effect of zinc on the aggregation kinetics was tested 
(Figure 5B).  A HEPES buffer with 10mM ZnCl2 at pH 7.5 was prepared, and the peptide 
was added.  After reacting for over fifteen hours, there were no signs of aggregation. 
In an effort to speed up the kinetics of the aggregation, high salt concentrations 
were added to the solutions.  NNQQNY in 10mM phosphate buffer with 300mM NaCl at 
pH 7.4 and 25ºC still showed only a slight increase in absorbance (Figure 5C).  The 
temperature was raised to 30ºC in a further attempt to increase the rate (Figure 5D).  
Unfortunately, the rise in absorbance was still small until near the 30 hour mark, at which 
time an abrupt increase was observed. 
Because the reaction time was so long and the increase in turbidity was so low for 
NNQQNY, the heptapeptide GNNQQNY was used instead.  In general, GNNQQNY 
showed a significantly higher change in turbidity compared to the hexapeptide 
counterpart.  Several turbidity measurements of 0.30 mg/mL of GNNQQNY in 10mM 
phosphate buffer at pH 7.4 and 25°C were performed.  Without stirring, the graph 
appeared jagged due to a lack of homogeneity in solution.  This graph could be corrected 
to show the general rise in absorbance (Figure 6A).  When stirred, the kinetics of the 
aggregation could be seen much more clearly (Figure 6B), but continued to be jagged due 
to peptides crashing out of solution.  With attenuated stirring, a much smoother kinetic 
graph was observed (Figure 6C).  Still, the reaction took nearly 100 hours to finish, which 
is impractical for comparing several peptides. 
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Determination of Ideal Aggregation Conditions 
This long time course indicated that the conditions for the peptide aggregation 
were not ideal.  In order to optimize the reaction, a series of aggregations was performed 
with varied pH and salt concentration, measuring the post-aggregation monomer 
concentrations.  The buffers used were: 0.01M HCl (at pH 2), 10mM sodium acetate, 
10mM boric acid, 10mM Tris(Hydroxymethyl) Aminomethane (at pH 4, 6, 8, and 10), 
10mM NaPi (at pH 8), and 10mM KPi, 300mM NaCl (at pH 7.4).  The first series of 
reactions is summarized in Table 1.  It indicated that the Tris buffer at pH 8 and the high 
salt concentration both increased the reaction rate. 
This was not entirely conclusive, however, because each sample had different 
starting concentrations of the peptide and DMSO.  Therefore, a second series of reactions 
was performed, as summarized in Table 2.  In this series, the initial concentration of each 
sample was set to 1mM, or 0.67 mg/mL, and the DMSO concentration was kept constant 
at 0.7%.  The samples were first run for two days without agitation, and then for another 
two days with agitation.  Unfortunately, the samples were not agitated equally, which 
makes the data unreliable.  In pH 4 buffer over half of the original peptide had 
aggregated, but this is possibly due to extra agitation time.  The only corresponding data 
was in the high salt buffer, which still showed one of the higher aggregation percentages. 
Although the pH series proved mostly inconclusive, it was determined that 
increasing the salt concentration should increase the aggregation rate.  The next step was 
to isolate the ideal concentration for kinetic studies.  The turbidity kinetics of several high 
concentrations of GNNQQNY in 10mM KPi and 300mM NaCl at pH 7.4 were 
monitored.  Amongst 0.63 mg/mL, 0.90 mg/mL, and 1.5 mg/mL, the lowest 
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concentration was found to have the clearest trace (Figure 7A).  The two higher 
concentrations seemed to aggregate too quickly, because of which the lag phase in the 
sigmoidal curve was not apparent.  Post-aggregation monomer measurements of the 
samples showed that 56% of the 0.63 mg/mL GNNQQNY, 58% of the 0.90 mg/mL, and 
71% of the 1.5 mg/mL had aggregated (Table 3).  The ideal concentration was further 
isolated by observing the kinetics of 0.49 mg/mL, 0.55 mg/mL, and 0.60 mg/mL (Figure 
7B).  The 0.60 mg/mL sample had the clearest sigmoidal kinetics and was determined to 
be the best concentration for further studies. 
 
GNNQQNY Mutant Turbidity Studies 
After the optimal conditions for aggregation were determined, turbidity 
measurements of the mutants of GNNQQNY were performed.  The first series measured 
the aggregation of GNNQQNY at 0.60 mg/mL, GNNQQLY at 0.60 mg/mL, and 
GNNQQLY at 0.50 mg/mL (Figure 8A).  An effort was made to test GNLQQNY, but the 
initial concentration of the peptide was too low.  Although the mutant was properly 
dissolved in solution, it was nearly entirely filtered out by the 3kDa filters.  The 0.50 
mg/mL GNNQQLY solution did not show significant aggregation, while the 0.60 mg/mL 
GNNQQLY showed a drastically reduced aggregation rate.  The post-aggregation 
monomer concentrations of this experiment showed that about 60% of the wild type 
peptide aggregated.  About 57% of the GNNQQLY at 0.60mg/mL aggregated, while only 
18% of the peptide at 0.50mg/mL aggregated (Table 3).  It is important to note, however, 
that these monomer measurements were taken several weeks after the kinetics 
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experiments.  Therefore, it is difficult to tell when the mutants reached thermodynamic 
equilibrium, or if they had even reached it by the time the measurements were taken. 
Another series of mutants was tested, with GNNQQNY, GLNQQNY, and 
GNNQQLY at concentrations of 0.60 mg/mL (Figure 8B).  Once again GNLQQNY was 
not able to be used due to being filtered out of solution.  GNNQQLY did not show 
significant aggregation on its kinetic trace, and only 33% of the monomers aggregated.  
The trace of GLNQQNY showed some aggregation, but at a significantly reduced rate.  
Its monomer concentration, taken several weeks after the kinetic experiment, showed that 
77% of the peptide aggregated (Table 3).  Again, it is difficult to determine at what point 
the reaction reached equilibrium. 
To determine the validity of the results, it was important to measure their 
repeatability.  This was done by performing a triplicate reaction of GNNQQNY at 0.50 
mg/mL (Figure 9).  Each sample was treated identically, with the same concentrations in 
the same 10mM KPi, 300mM NaCl buffer.  The results of this experiment showed two 
kinetic traces that were similar, with the t1/2 differing only by approximately two hours.  
The third sample did not show any sigmoidal curve or a significant change in absorbance.  
However, the post-aggregation monomer concentrations for this series of experiments 
shows that the peptides aggregated equally, each having about 50% of the monomers 
aggregate (Table 3). 
 
Fluorescence Data 
Along with turbidity studies, fluorescence spectrometry was used in an effort to 
monitor peptide aggregation.  A proton NMR of the recrystallized thioflavin T in D2O 
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indicated a pure product (Figure 10).  The GNNQQNY aggregation experiment run on 
the spectrometer showed no evidence of aggregation.  To determine whether ThT binds 
to GNNQQNY aggregates, three different concentrations of aggregated samples were 
tested.  Both the 0.63 mg/mL and 0.90 mg/mL samples showed significant increases in 
intensity over the ThT alone in buffer (Figure 11).  The fluorescence of the 0.63 mg/mL 
sample was over twice as intense, and the 0.90 mg/mL sample was three times as intense.  
The 1.50 mg/mL sample of aggregated GNNQQNY, however, showed no significant 
increase in intensity.  This could indicate that the highly concentrated sample aggregated 
differently, either achieving more mature fibrils or perhaps not forming true amyloids due 
to the high reaction rate. 
 
 
 28
Discussion: 
 
In order to test the importance of the specific amino acids in the amyloidogenic 
peptide GNNQQNY, several different mutants were synthesized.  It was hypothesized 
that mutating the various asparagines would significantly alter the kinetics of 
aggregation, since these residues have been demonstrated by computer model (33) and 
crystal structure (34) to be involved in interstrand and intrastrand hydrogen bonding.  
Leucine is similar in size to asparagine (Figure 12A and B), although it has an SP3 bond 
character instead of the SP2 found in asparagine.  The major difference between the two 
residues is that leucine is hydrophobic and will not form hydrogen bonds.  Therefore, 
mutating the asparagines into leucines may further clarify the aggregation process.  If the 
leucine mutants show an increased aggregation rate, then it is possible that the hydrogen 
bonds are not vital to the assembly of oligomeric structures.  On the other hand, if the 
mutants aggregate more slowly, it may indicate that the interstrand and intrastrand 
hydrogen bonds are a major component of the aggregation process. 
 
Optimization of Aggregation Conditions 
An important factor in the experimental process was determining the ideal 
conditions for the aggregation of the peptides.  The first notable condition was agitation, 
which was shown to accelerate the aggregation process.  This can be clearly seen from 
the pH optimization experiments (Table 2).  The pH 4 buffer solution had no appreciable 
aggregation after two nights sitting motionless, but over 50% of the peptide aggregated 
after two nights of being shaken.  Agitation was also important for turbidity 
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measurements.  Stirring the samples on the UV/VIS ensured that the solution was 
homogenous and that an accurate assessment of the turbidity was being made. 
Another factor that may have been important was the DMSO concentration.  
DMSO is known to keep amyloidogenic peptides soluble, which is why it was used to 
initially dissolve the peptides.  Generally the concentration is kept low by using minimal 
DMSO and diluting the solution with buffer.  Early in the tests, however, the DMSO 
percentage was not accounted for when diluting the peptide solutions to the desired 
concentration.  Although the specific effects of different DMSO percentages were not 
tested, there was some concern that it may alter the aggregation kinetics.  Therefore, in 
order to ensure that it would not be responsible for any differences in kinetics, the DMSO 
was kept constant at 0.7% for all samples. 
Two series of experiments were performed to find the optimal pH for the peptide 
aggregation.  Unfortunately, the pH tests were rather inconclusive.  During the first series 
(Table 1), it seemed that pH 8 was ideal, since it showed the greatest peptide aggregation.  
This result was uncertain, however, because each sample had a slightly different initial 
concentration of peptide and DMSO.  While this difference was small, it may have been 
great enough to affect the results.  Therefore, a second series of tests was run, keeping the 
concentrations identical for each sample.  This experiment turned out to be even less 
conclusive.  This time, the peptides did not aggregate until they were agitated, but due to 
an error in the shaking process they were not agitated equally.  Since agitation is so 
important to the peptide aggregation, any variability in the shaking would alter the 
results.  Although neither experiment was completely conclusive, the tests did seem to 
indicate that the pH was not as important for the aggregation as other factors, such as 
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stirring.  Therefore, it was determined that a pH of 7.4 would be acceptable for 
aggregation experiments. 
Perhaps the most important condition turned out to be the salt concentration.  
Based on the turbidity measurements, it seemed clear that the peptides did in fact 
aggregate, but that the rate was too slow for efficient experimentation.  Increasing the salt 
concentration sped up the reaction by forcing the aggregated peptides out of solution.  
This effect can be seen in the pH tests (Tables 1 and 2), in which peptides in high salt 
buffer aggregated more readily than most of the others.  Through all of these conditions, 
it was determined that a buffer consisting of 10mM KPi and 300mM NaCl at pH 7.4 was 
optimal for the aggregation kinetics. 
 
Aggregation Kinetics of NNQQNY and GNNQQNY 
Initially, the hexapeptide NNQQNY was intended to be the main control peptide.  
This did not work, however, because NNQQNY did not demonstrate a clear sigmoidal 
curve in the turbidity reaction (Figure 5).  It did seem to aggregate, since the peptide 
solution increased in absorbance more than the buffer alone.  This rise was very small, 
however, and could not be accurately studied.  The heptapeptide counterpart GNNQQNY 
was then used instead.  This peptide aggregated much more readily than NNQQNY 
(Figure 6), and it gave a much clearer kinetic trace.  This result is very interesting; by 
simply adding a glycine to the peptide, the turbidity studies change drastically.  
Moreover, glycine residues are generally expected to break β-strands and reduce 
aggregation, but in this case it seems to be vital to aggregation. 
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It is strange that the addition of a glycine, an amino acid known to interfere with 
the formation of β-sheets, would aid in the peptide aggregation.  Perhaps glycine is not 
the ideal residue to induce aggregation.  Instead, an amino acid with a higher β-sheet 
propensity could potentially increase the rate even further.  It would be very informative 
to create another mutant of GNNQQNY, replacing the glycine residue with a different 
amino acid.  Such an experiment could elucidate the importance of the seventh residue. 
A likely reason for the lack of turbidity with NNQQNY is that the peptides are 
simply not assembling into large enough structures.  They may be forming β-sheets, but 
unless they are able to aggregate into the oligomeric superstructure the turbidity will not 
increase.  It is possible that the glycine on the GNNQQNY provides an interaction point 
for other peptides, allowing the large aggregates to form.  This can be seen in the crystal 
structure data, where the glycine residues seem to interact with other peptides, stabilizing 
the overall structure (34).  A Congo red binding assay and circular dichroism would be 
useful in determining whether NNQQNY takes on a β-sheet structure in solution. 
 
Leucine Mutants of GNNQQNY 
When the leucine mutants of GNNQQNY were tested, both GLNQQNY and 
GNNQQLY demonstrated lower aggregation rates than the wild type peptide (Figure 8).  
GNNQQLY also seemed to have less of its peptide monomers aggregate together than 
the wild type (Table 3).  GLNQQNY, on the other hand, showed an increase in monomer 
aggregation over GNNQQNY.  It is difficult to determine when the mutant peptides 
reached thermodynamic equilibrium, however, since the kinetic traces of these peptides 
did not show the final plateau and the monomer concentrations were measured several 
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weeks after the kinetic experiments.  It seems that the Leu2 and Leu6 mutants both 
reduce the rates of aggregation, while Leu2 may still increase the total aggregate formed 
at thermodynamic equilibrium.  This means that while GLNQQNY takes longer to 
aggregate, its equilibrium will have more aggregated material than the wild type.  It is 
also possible that Leu6 will have a similar result if left to react for a long enough period 
of time. 
Both of these peptides have mutations on the dry interface of the steric zipper.  
Changing Asn2 and Asn6 to Leu2 and Leu6 would be expected to interfere with the 
hydrogen bonding found in the wild type.  It is reasonable, therefore, to expect that such 
mutations would reduce the aggregation rate.  Even though the hydrophobic leucine 
residues would tend to prefer a dry environment, the loss of hydrogen bonding capacity 
may interfere with the peptides’ ability to form the dry interface.  While the lack of 
hydrogen bonding increases the total reaction time, the extra hydrophobicity may still 
cause more of the peptide monomers to aggregate at equilibrium.  This would explain 
how the Leu2 mutant shows a decreased reaction rate, but an increased amount of 
aggregated material. 
It is also possible that leucine’s slight difference in shape, due to its SP3 
character, inhibits the aggregation through steric interactions.  Since it is not the exact 
same shape as asparagine, it may not fit properly into the highly ordered steric zipper.  
Unnatural amino acids could be designed that are more similarly shaped to asparagine, 
while still lacking the hydrogen bond capacity (Figure 12).  The aggregation kinetics of a 
mutant peptide using such an amino acid could help to clarify the importance of the steric 
interactions.  Still, this preliminary data seems to support the computer models and 
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indicates that the side-chain hydrogen bonds may be very important for the peptide 
aggregation.  The experiments certainly need to be repeated, however, to ensure 
accuracy. 
Unlike the Leu2 and Leu6 mutants, the third leucine mutant GNLQQNY seemed 
to drastically increase the aggregation rate.  Unfortunately, the kinetics of the reaction 
and the monomer concentrations could not be monitored because the peptide crashed out 
of solution too quickly.  This lack of hard evidence makes it difficult to draw a 
conclusion.  The aggregate formed may not even be an actual amyloid-like structure.  
Instead, the peptide may have lost solubility in the high salt solution.  Although this 
seems unlikely, since the very similar GLNQQNY was soluble, there is currently no 
evidence to study.  Circular dichroism needs to be performed to verify the identity of the 
secondary structure and tell for certain whether or not the Leu3 mutant has formed a true 
aggregate. 
Still, there is logic to the idea that the Leu3 mutant would increase the 
aggregation rate.  Asn3 is located on the wet interface, and is generally involved 
hydrogen bonding interactions with water molecules.  Leu3, being hydrophobic, would 
not favor a wet interface.  Instead, it is possible that the leucines from different molecules 
will interact through hydrophobic forces.  Such an interaction could potentially accelerate 
the aggregation process by destroying the wet interface and creating a new hydrophobic 
interface.  This hypothesis could be tested by mutating Gln5 to a leucine or other 
hydrophobic residue, making GNNQLNY.  Since Gln5 is also on the wet interface, 
mutating it to a hydrophobic residue may have a similar effect on the aggregation rate. 
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 Fluorescence Spectrometry 
In addition to the turbidity studies, fluorescence spectrometry was used to monitor 
the aggregation of GNNQQNY.  This was done using the fluorescent dye thioflavin T, 
which was chosen due to its known ability to bind to amyloid fibrils formed by 
Alzheimer’s Aβ.  It became problematic, however, because it has not been proven to bind 
to all amyloidogenic peptides, including many of the smaller ones.  Therefore, it is 
unclear how ThT it interacts with GNNQQNY.  During the aggregation studies, no 
change in fluorescence was seen.  This could mean that the dye did not properly bind to 
the aggregating peptide, or that the peptide did not aggregate at all.  Since the solution 
was not stirred during the course of the experiment, it is possible that it simply failed to 
aggregate. 
To test the ThT, known aggregated samples were examined for fluorescence in 
the presence of the dye.  The lower concentrated samples fluoresced more than the ThT 
alone, but the highest concentrated sample did not (Figure 11).  This seems to indicate 
that the dye binds to some form of the peptide aggregate, but for some reason does not 
bind to highly concentrated samples.  It is possible that ThT will interact with 
intermediate oligomers of GNNQQNY but not the final fibril.  Since the highly 
concentrated sample is likely to have reached this final stage more readily, it may not 
bind ThT.  This hypothesis is not supported by the literature, however, which indicates 
that ThT only binds to mature fibrils.  It is more likely that the highly concentrated 
sample aggregated so quickly that it could not form the regular superstructure of the 
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amyloid.  Instead, the peptides may have simply massed together without forming fibrils 
for the ThT to bind to. 
Another aggregation experiment needs to be performed, with stirring, so that the 
effect of ThT can be monitored over the course of the reaction.  It would also be helpful 
to perform a positive control on the ThT by monitoring the aggregation of Aβ.  It is 
known that the dye should bind to the Alzheimer’s peptide, so this experiment would 
verify that the thioflavin T is functioning properly.  Since the proton NMR indicates that 
the ThT is properly formed and pure, however, it is unlikely that there is a problem with 
the dye itself (Figure 10). 
 
Reliability of Data 
Of course, it is always important to check the veracity of the data.  Based on 
LCMS and proton NMR, the peptides were at least 80% pure, and were usually around 
95% pure.  This high purity makes it unlikely that the changes in turbidity or aggregation 
were due to the presence of contaminants.  Also, the data proved to be fairly repeatable.  
During the triplicate GNNQQNY aggregation, two of the traces were similar, with half-
times differing by only two hours (Figure 9).  The third sample did not give a good 
kinetic trace.  However, the peptide in this sample still seems to have aggregated, since 
there is a general increase in absorption early on.  It is likely that there were problems 
with the stirring, which would cause the aggregates to precipitate out and would therefore 
alter the absorption.  This is supported by the post-aggregation monomer concentrations, 
which show that all of the samples aggregated equally (Table 3).  Such data indicates that 
the turbidity measurements do not always prove whether or not aggregates have formed.  
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Clearly, it is important to repeat experiments to verify the results.  With enough repeated 
data, it should be possible to come to a reliable conclusion. 
A major question that must be asked is exactly what sort of aggregate has formed.  
Turbidity measurements are not necessarily indicative of amyloid formation.  Since 
studies of GNNQQNY aggregation have been published describing the amyloid 
formation, it is unlikely that any other sorts of aggregates are forming.  Still, it is 
important to verify the identity of the aggregate using Congo red dye, circular dichroism, 
or microscopic studies of the fibrils. 
 
Future Experiments 
There are still many experiments that can be performed to further elucidate the 
driving forces behind GNNQQNY aggregation.  As previously stated, many of the 
experiments, especially with the leucine mutants, need to be repeated to ensure their 
accuracy.  It would also be informative to make Gly1 mutants of GNNQQNY, 
particularly with amino acids of high β-sheet propensity, to study the function of this 
residue.  NNQQNY should be studied in more depth, along with its leucine and valine 
mutants.  Of particular interest would be monitoring the aggregation of NLQQNY, to see 
if it had a similar effect as the Leu3 mutant of GNNQQNY.  More post-aggregation 
monomer concentration studies need to be performed.  This technique is useful in 
studying the degree of aggregation for the peptide.  Furthermore, it can be used to 
determine if NNQQNY is aggregating into β-sheets without forming larger oligomers.  If 
the monomer concentration decreases in the reaction, then NNQQNY is in fact forming 
aggregates.  It is also necessary to determine the identity of the aggregates using Congo 
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red or circular dichroism.  This is particularly important in determining if GNLQQNY is 
accelerating amyloid formation or simply causing a different form of peptide deposition.  
If the Leu3 mutant did in fact create an amyloid so quickly, Asn3 would be a very 
interesting residue for further study. 
In addition, new mutants should be made with unnatural amino acids.  The amino 
acid in Figure 12C is a much better mimic of asparagine than leucine is.  Due to its 
double bond, it has SP2 characteristics and is planar.  Also, it has a similar size and shape 
to asparagine.  Unlike the wild type amino acid, however, it cannot form hydrogen bonds.  
A GNNQQNY mutant with this amino acid could be used to examine the importance of 
the hydrogen bonding abilities while maintaining the steric characteristics.  Similarly, the 
amino acids in Figures 12D and 12E can mimic the general size and shape of asparagine, 
but have different sized residues that could be give information of the steric allowance.  It 
would also be interesting to create a peptide with a ring structure in the place of the Asn2 
and Gln4 side chains, which would imitate the structure formed by hydrogen bonding 
interactions.  Since it would be a fixed structure it may increase the aggregation rate. 
 
Conclusion 
This series of experiments was an effort to study the driving forces of 
GNNQQNY aggregation.  A buffer consisting of 10mM KPi and 300mM NaCl at pH 7.4 
with agitation was determined to be ideal for the aggregation.  The Gly1 of the peptide 
was shown to be of importance, potentially aiding in the formation of larger oligomeric 
structures.  Preliminary data shows that Leu2 and Leu6 mutants slow the aggregation 
rate, possibly due to their inability to form hydrogen bonds.  Although the rate was 
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decreased, Leu2 actually seemed to increase the amount of aggregate formed at 
thermodynamic equilibrium, which may be caused by the increased hydrophobicity of the 
peptide.  Meanwhile, the Leu3 mutant seems to drastically increase the rate of 
aggregation.  While there are many experiments left to perform on the peptide 
GNNQQNY, this research has laid an important groundwork for future studies into the 
aggregation of small peptides. 
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Figures and Tables: 
 
Figure 1:  GNNQQNY and Leucine Mutant Structures. 
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Figure 2:  NNQQNY and Mutant Structures. 
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Figure 3:  Proton NMR Spectra for GNNQQNY in D2O. 
 
 
 
Figure 4:  LCMS Data for GNNQQNY and its Mutants. 
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Figure 5:  NNQQNY Turbidity Kinetics.  The traces were unclear and difficult to study, 
showing only small increases in absorption over long periods of time. 
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Figure 6:  GNNQQNY Turbidity Kinetics.  The jagged areas in the traces are caused by 
the precipitation of the aggregates, which alters the absorption due to the loss of 
peptides from solution. 
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B) 
GNNQQNY (0.3mg/mL) aggregation in 10 mM NaPi, pH7.4, 25oC, 
with stirring
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C) 
GNNQQNY (0.3mg/mL) aggregation in 10 mM NaPi, pH7.4, 25oC, 
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Figure 7:  Turbidity of GNNQQNY at Different Concentrations.  The traces in B show a 
break at 1500min due to the cuvettes being removed from the UV/VIS to be 
examined visually.  This action shakes the solution, suspending any precipitate 
and increasing absorption. 
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B) 
Aggregation kinetics of GNNQQNY in 10 mM NaPi, pH 7.4, 
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Figure 8:  GNNQQNY Mutant Turbidity Kinetics.  The sudden jumps seen in the traces 
are due to the cuvettes being removed from the UV/VIS to be examined visually.  
This action shakes the solution, suspending any precipitate and increasing 
absorption. 
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Figure 9:  Triplicate GNNQQNY Turbidity Kinetics.  Trial 2 shows a decrease in 
absorption after 400min due to aggregates precipitating from the solution.  The 
trace for Trial 3 indicates some aggregation, but remains jagged due to the 
aggregates precipitating. 
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Figure 10:  Proton NMR Spectra from Thioflavin T. 
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Figure 11:  Fluorescent Spectrometry of GNNQQNY Aggregates. 
 
A)  ThT Alone 
 
 
 
B)  0.63mg/mL GNNQQNY 
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Figure 11 Continued. 
 
C)  0.90mg/mL GNNQQNY 
 
 
 
D)  1.50mg/mL GNNQQNY 
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Figure 12:  Alternative Amino Acids. 
 
A)  Natural Asparagine    B)  Natural Leucine 
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Table 1: Percent of GNNQQNY Aggregated at varied pH 
Buffer 
Initial Monomer 
Concentration 
(mg/mL) 
Final Monomer 
Concentration 
(mg/mL) 
Percent of Peptide 
Aggregated 
0.01 HCl pH 2 0.122 0.116 4.91% 
Tris pH 4 0.173 0.162 6.36% 
Tris pH 6 0.156 0.130 16.7% 
Tris pH 8 0.160 0.103 35.6% 
Tris pH 10 0.157 0.131 16.6% 
300mM NaCl pH 7.4 0.134 0.081 39.6% 
 
 
 
Table 2: Percent of GNNQQNY Aggregated at varied pH, 
with Initial Peptide Concentration of 1mM 
Buffer 
Monomer 
Concentration 
without agitation 
(mM) 
Monomer 
Concentration after 
agitation 
(mM) 
Percent of Peptide 
Aggregated 
0.01 HCl pH2 1.05 *no reading* 0% 
Tris pH 4 0.980 0.432 56.8% 
Tris pH 6 0.976 1.09 0% 
Tris pH 8 0.996 0.992 0.8% 
NaPi pH 8 1.01 1.04 0% 
Tris pH 10 0.957 0.970 3.0% 
300mM NaCl pH 7.4 0.905 0.919 8.1% 
 
Note:  The agitation times for each sample were inconsistent.  Also, no measurement was 
taken for the sample at pH 2 after agitation, due to possible contamination of the sample. 
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Table 3: Peptide Monomer Concentrations 
in 10mM KPi, 300mMNaCl Buffer 
Experiment Peptide 
Concentration 
Before 
Aggregation 
(mg/mL) 
Concentration 
After 
Aggregation 
(mg/mL) 
Percent of 
Peptide 
Aggregated 
Concentration 
Optimization 
GNNQQNY 0.63 0.28 56% 
GNNQQNY 0.90 0.38 58% 
GNNQQNY 1.50 0.44 71% 
First Mutant 
Experiment 
GNNQQNY 0.60 0.24 60% 
GNNQQLY 0.60 0.26 57% 
GNNQQLY 0.50 0.41 18% 
Second Mutant 
Experiment 
GNNQQNY 0.60 0.26 57% 
GLNQQNY 0.60 0.14 77% 
GNNQQLY 0.60 0.40 33% 
Triplicate 
Experiment 
GNNQQNY 0.50 0.25 50% 
GNNQQNY 0.50 0.26 48% 
GNNQQNY 0.50 0.24 52% 
 
Note:  The Post-Aggregation Monomer Concentrations were measured several weeks 
after the initial aggregation experiment.  Since the kinetic data did not show the end-
plateau for every mutant, it is difficult to say when the reactions reached completion, or if 
they were complete when the measurements were taken. 
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Appendix: 
 Amino Acid Abbreviations 
Amino Acid Three Letter One Letter 
Alanine……………………………….… Ala .…………………………………..... A 
Asparagine…………………………..…. Asn …………………………………….. N 
Aspartate………………………….……. Asp ………………………………..…… D 
Arginine……………………….……….. Arg ……………………………….……. R 
Cysteine…………………….………….. Cys ……………………………….……. C 
Glutamate………………….…………… Glu ……………………………….……. E 
Glutamine……………….……………… Gln ………………………………..…… Q 
Glycine……………….………………… Gly ………………………………..…… G 
Histidine……………………………….. His ……………………………….……. H 
Isoleucine………………………………. Ile ……………………………….…….. I 
Leucine…………..……………………... Leu ……………………………….……. L 
Lysine…………..………………………. Lys ……………………………….……. K 
Methionine…….……………………….. Met ………………………………..…… M 
Phenylalane…….…………………….. Phe ……………………………….……. F 
Proline………….………………………. Pro ……………………………….……. P 
Serine…………..……………………….. Ser ……………………………….……. S 
Threonine……..………………………… Thr ……………………………….……. T 
Tryptophan…..………………………….. Trp ………………………………..…… W 
Tyrosine……..………………………….. Tyr ………………………………...……Y 
Valine……...…………………………….. Val …………………………………...... V 
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